JPWO2022114163A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022114163A5 JPWO2022114163A5 JP2022565479A JP2022565479A JPWO2022114163A5 JP WO2022114163 A5 JPWO2022114163 A5 JP WO2022114163A5 JP 2022565479 A JP2022565479 A JP 2022565479A JP 2022565479 A JP2022565479 A JP 2022565479A JP WO2022114163 A5 JPWO2022114163 A5 JP WO2022114163A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023195187A JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020198044 | 2020-11-30 | ||
| JP2020198044 | 2020-11-30 | ||
| JP2021110912 | 2021-07-02 | ||
| JP2021110912 | 2021-07-02 | ||
| PCT/JP2021/043538 WO2022114163A1 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195187A Division JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022114163A1 JPWO2022114163A1 (https=) | 2022-06-02 |
| JPWO2022114163A5 true JPWO2022114163A5 (https=) | 2023-07-25 |
| JP7393774B2 JP7393774B2 (ja) | 2023-12-07 |
Family
ID=81754499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Active JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
| JP2023195187A Pending JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195187A Pending JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240002531A1 (https=) |
| EP (1) | EP4253420A4 (https=) |
| JP (2) | JP7393774B2 (https=) |
| KR (1) | KR20230114747A (https=) |
| AU (1) | AU2021387127A1 (https=) |
| CA (1) | CA3199473A1 (https=) |
| IL (1) | IL303154A (https=) |
| MX (1) | MX2023005864A (https=) |
| TW (2) | TW202546008A (https=) |
| WO (1) | WO2022114163A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| US20250228943A1 (en) | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| PT2330131E (pt) * | 2009-12-07 | 2015-01-14 | Fundació Privada Institució Catalana De Recerca I Estudis Avancats | Anticorpos contra a variante truncada de her-2 ctf-611 |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| US11851479B2 (en) * | 2018-06-18 | 2023-12-26 | Dxdiscovery, Inc. | Methods and compositions for pertussis diagnosis |
| US20250222029A1 (en) * | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
-
2021
- 2021-11-29 TW TW114129312A patent/TW202546008A/zh unknown
- 2021-11-29 JP JP2022565479A patent/JP7393774B2/ja active Active
- 2021-11-29 CA CA3199473A patent/CA3199473A1/en active Pending
- 2021-11-29 TW TW110144472A patent/TW202229359A/zh unknown
- 2021-11-29 KR KR1020237017469A patent/KR20230114747A/ko active Pending
- 2021-11-29 AU AU2021387127A patent/AU2021387127A1/en active Pending
- 2021-11-29 EP EP21898135.5A patent/EP4253420A4/en active Pending
- 2021-11-29 IL IL303154A patent/IL303154A/en unknown
- 2021-11-29 MX MX2023005864A patent/MX2023005864A/es unknown
- 2021-11-29 US US18/038,185 patent/US20240002531A1/en active Pending
- 2021-11-29 WO PCT/JP2021/043538 patent/WO2022114163A1/ja not_active Ceased
-
2023
- 2023-08-04 US US18/365,828 patent/US11981747B1/en active Active
- 2023-11-16 JP JP2023195187A patent/JP2024020436A/ja active Pending